Journal Article Ppublish 3 citations
PubMed: 39418391 DOI: 10.1210/clinem/dgae694
Associations of AMH in Midreproductive Years with Bone Mineral Density and Turnover Markers in Midlife.
J Clin Endocrinol Metab 110(7):1836-1845
Authors: Siwen Wang, Elaine W Yu, Marie-France Hivert, Sheryl L Rifas-Shiman, Jan L Shifren, Maryam Kazemi, Emily Oken, Jorge E Chavarro
Affiliations
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
- Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
- Division of Chronic Disease Research across the Lifecourse (CoRAL), Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.
- Diabetes Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Abstract
CONTEXT
The concentration of circulating anti-Müllerian hormone (AMH) predicts short-term (3-5 years) bone loss around menopause. Whether AMH during midreproductive years predicts bone health over a decade later is unknown.
OBJECTIVE
To study the association of AMH levels in midreproductive years with bone density and turnover biomarkers measured after ∼14 years of follow-up.
METHODS
We assessed plasma AMH in 2003-2006 (mean 37.0 years, SD 5.1) among 450 parous women (71% White) in a US longitudinal cohort, and bone mineral density (BMD; spine, hip, and femoral neck, measured by dual-energy X-ray absorptiometry) in 2017-2021 (mean 51.0 years, SD 5.1). Secondary outcomes were plasma levels of procollagen type I N-propeptide (PINP) and type I collagen cross-linked C telopeptide (CTX-I).
RESULTS
In linear regression models adjusted for demographics and lifestyle, compared with women with AMH >3.5 ng/mL, those with AMH <1.0 ng/mL had lower BMD (g/cm2) at follow-up (beta [95% CI] spine: -.06 [-0.10, -0.02]; hip: -.05 [-0.08, -0.02]; femoral neck: -.03 [-0.06, 0.00]) and higher bone turnover markers (beta [95% CI] PINP: .36 SD [0.10, 0.63]; CTX-I: .34 SD [0.07, 0.60]). The association of AMH with spine BMD was more pronounced among postmenopausal women in contrast to associations with bone turnover markers, which were more pronounced among women who had not yet reached menopause. The associations between AMH and BMD were primarily mediated by menopausal status at follow-up.
CONCLUSION
Lower AMH during midreproductive years is associated with lower BMD and higher bone turnover 14 years later. Ovarian reserve during midreproductive years may be a valuable predictor of long-term bone health.
MeSH
Bone Remodeling, Collagen, Ovarian Reserve, Menopause, Bone Density, Plasma, Spine